伊匹单抗/纳武利尤单抗治疗同源重组缺陷种系变异的转移性胰腺或胆管癌患者。
Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants.
机构信息
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
出版信息
JAMA Oncol. 2022 Jun 1;8(6):1-3. doi: 10.1001/jamaoncol.2022.0611.
Abstract
This case series describes ipilimumab/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency (HRD) pathogenic germline variants (PGVs).
摘要
本病例系列描述了具有同源重组缺陷（HRD）种系变异（PGV）的转移性胰腺或胆管癌患者接受伊匹单抗/纳武利尤单抗治疗的情况。
相似文献
1
Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants.伊匹单抗/纳武利尤单抗治疗同源重组缺陷种系变异的转移性胰腺或胆管癌患者。
JAMA Oncol. 2022 Jun 1;8(6):1-3. doi: 10.1001/jamaoncol.2022.0611.
2
Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.尼伏单抗联合伊匹单抗治疗乳头状肾细胞癌患者的疗效一般。
Jpn J Clin Oncol. 2021 Apr 1;51(4):646-653. doi: 10.1093/jjco/hyaa229.
3
Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.纳武利尤单抗联合伊匹单抗与舒尼替尼治疗晚期肾细胞癌的不良事件和成本的时间趋势。
Future Oncol. 2022 Mar;18(10):1219-1234. doi: 10.2217/fon-2021-1109. Epub 2021 Dec 23.
4
Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature.尼伏鲁单抗联合伊匹单抗致转移性肉瘤样肾细胞癌内分泌病和急性间质性肾炎：病例报告及文献复习。
Front Immunol. 2022 Aug 16;13:993622. doi: 10.3389/fimmu.2022.993622. eCollection 2022.
5
First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.一线纳武利尤单抗联合伊匹单抗与舒尼替尼治疗转移性肾细胞癌：成本效果分析。
JAMA Oncol. 2019 Apr 1;5(4):491-496. doi: 10.1001/jamaoncol.2018.7086.
6
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.一线治疗转移性肾细胞癌时因免疫相关不良事件导致纳武利尤单抗联合伊匹单抗早期治疗中断的预后影响：一项多机构回顾性研究。
Target Oncol. 2021 Jul;16(4):493-502. doi: 10.1007/s11523-021-00825-2. Epub 2021 Jun 26.
7
Nivolumab plus ipilimumab in advanced renal-cell carcinoma.纳武利尤单抗联合伊匹木单抗治疗晚期肾细胞癌。
Lancet Oncol. 2018 May;19(5):e232. doi: 10.1016/S1470-2045(18)30257-2. Epub 2018 Mar 29.
8
Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study.纳武单抗联合伊匹单抗治疗未行前期肾切除术的晚期肾细胞癌时原发性肾病灶及转移病灶的肿瘤反应：一项多机构研究的初步结果
Int J Urol. 2021 Oct;28(10):1075-1076. doi: 10.1111/iju.14635. Epub 2021 Jul 3.
9
Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma.三例血液透析患者转移性肾细胞癌接受纳武利尤单抗联合伊匹单抗治疗。
In Vivo. 2021 Nov-Dec;35(6):3585-3589. doi: 10.21873/invivo.12663.
10
Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.纳武利尤单抗联合伊匹单抗在一名转移性透明细胞肾细胞癌伴去分化肉瘤样变和血液透析终末期肾病患者中的安全有效应用。
Cancer Treat Res Commun. 2021;27:100349. doi: 10.1016/j.ctarc.2021.100349. Epub 2021 Mar 10.
引用本文的文献
1
Molecular tumor boards in pancreatic cancer with liver metastasis: A case report.伴有肝转移的胰腺癌分子肿瘤委员会：一例报告
World J Hepatol. 2025 Jul 27;17(7):106993. doi: 10.4254/wjh.v17.i7.106993.
2
Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer.靶向“不可成药”的KRAS：胰腺癌治疗的突破、挑战与机遇
Cancer Biol Med. 2025 Jul 7. doi: 10.20892/j.issn.2095-3941.2025.0122.
3
Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cancer.同源重组-DNA损伤反应缺陷增加了胰腺癌的肿瘤突变负荷和新抗原负载，但未增加效应T细胞密度和克隆多样性。
Exp Hematol Oncol. 2025 Jun 18;14(1):86. doi: 10.1186/s40164-025-00673-0.
4
The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancer.同源重组缺陷在胃肠道癌中的预后及预测价值
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf141.
5
The Interplay Between DNA Repair and the Immune Microenvironment in Pancreatic Cancer.胰腺癌中DNA修复与免疫微环境之间的相互作用
Biomedicines. 2025 Apr 24;13(5):1031. doi: 10.3390/biomedicines13051031.
6
Improving outcomes of patients with pancreatic cancer.改善胰腺癌患者的治疗效果。
Nat Rev Clin Oncol. 2025 May 6. doi: 10.1038/s41571-025-01019-9.
7
Pancreatic cancer: failures and hopes-a review of new promising treatment approaches.胰腺癌：失败与希望——新的有前景的治疗方法综述
Explor Target Antitumor Ther. 2025 Mar 18;6:1002299. doi: 10.37349/etat.2025.1002299. eCollection 2025.
8
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.穿针引线：探索胰腺导管腺癌中的新型免疫疗法
Cancers (Basel). 2025 Feb 20;17(5):715. doi: 10.3390/cancers17050715.
9
Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management.遗传性胰腺癌：基因检测、早期检测策略及个性化管理的进展
J Clin Med. 2025 Jan 9;14(2):367. doi: 10.3390/jcm14020367.
10
Prognostic Accuracy of ypTNM Stage in Patients with Pancreatic Cancer in the Era of Modern Neoadjuvant Therapy.现代新辅助治疗时代胰腺癌患者ypTNM分期的预后准确性
Ann Surg Oncol. 2025 Apr;32(4):2799-2808. doi: 10.1245/s10434-024-16792-7. Epub 2025 Jan 5.
Zotero 插件